PDF) Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World | Fausto Salaffi - Academia.edu
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology
Dapsa Eng | PDF
PDF) Comparison of disease activity measures in early psoriatic arthritis in usual care
Frontiers | Harnessing Big Data, Smart and Digital Technologies and Artificial Intelligence for Preventing, Early Intercepting, Managing, and Treating Psoriatic Arthritis: Insights From a Systematic Review of the Literature
JCM | Free Full-Text | DNA Fragmentation in Viable and Non-Viable Spermatozoa Discriminates Fertile and Subfertile Subjects with Similar Accuracy | HTML
Descriptive statistics for DAPSA on weeks 12 and 24 | Download Table
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial - The Lancet Rheumatology
Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis | Scientific Reports
Psoriatic Arthritis Remission Compared With Very Low Disease Activity, DAPSA Criteria - Rheumatology Advisor
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice | The Journal of Rheumatology
PsA Remission, Response Cutoffs Identified for DAPSA Tool
The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology
Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World
RheumaHelper
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease | Arthritis Research & Therapy | Full Text
Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis - ScienceDirect
DAPSA versus cDAPSA: Do we need to use CRP? | Annals of the Rheumatic Diseases
Spearman correlations with the mCPDAI sum at baseline, on week 12 and... | Download Table
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease | Arthritis Research & Therapy | Full Text
What Should Be the Primary Target of “Treat to Target” in Psoriatic Arthritis?
Advances in the management of psoriatic arthritis | Nature Reviews Rheumatology
Digital Tools for Assessing Disease Severity in Dermatology. - Abstract - Europe PMC
Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a Quick QuantitativeC-reactive Protein Assay (Q-DAPSA) in Patients with Psoriatic Arthritis (PsA): A Prospective,national, Multicenter Study - ACR Meeting Abstracts
Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity - Helliwell - 2018 - Arthritis Care & Research - Wiley Online Library
The Patient's Perspective on Psoriatic Arthritis: What more can Rheumatologists do to Optimise Disease Management? - European Medical Journal
Home
DAPSA (Disease Activity in PSoriatic Arthritis) Score DAPSA = TJ + SJ + CRP + Activity + Pain =
